Project Grant R21CA299070
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$453K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Sloan-Kettering Institute for Cancer Research. The $256,487 grant, effective August 13, 2024, supports a 5-year research project to develop multimodal predictive models for non-small cell lung cancer (NSCLC) using real-world data sources such as circulating tumor DNA sequencing, tumor genomics, and clinician notes. The goal is to improve risk stratification and clinical...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $1,625,000.00 to Onc.ai, Inc. to validate the effectiveness of a radiomics-based multi-modal predictive model for identifying non-small cell lung cancer patients who will respond to PD-1/PD-L1 immunotherapy. The project aims to: 1) prospectively validate the predictive model in a multi-institutional clinical study; 2) evaluate the model's...
The National Cancer Institute (NCI) awarded a $1,280,908 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Exai Bio Inc., a small disadvantaged business located in Palo Alto, California. The award period runs from September 12, 2024 to August 31, 2026. The purpose of this Project Grant is to develop a novel assay and artificial intelligence (AI) model for the early detection of non-small cell lung cancer (NSCLC) and predicting its subtypes using a novel...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $592,866 to Georgia Tech Research Corp to develop ingestible nanosensors for early-stage colorectal cancer detection through breath-based biomarkers. The project aims to engineer nanosensors that can sense intestinal enzyme activities associated with tumor development and release volatile reporter signals that can be detected in breath via mass spectrometry. The goal is to...
This $968,999 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports a research study titled "OPTIMIZING SURVEILLANCE IN LUNG CANCER SURVIVORS WITH NOVEL IMAGING BIOMARKERS AND DEEP-LEARNING (OPTIMAL)". The study aims to optimize post-treatment surveillance for lung cancer survivors by incorporating risk-based strategies that leverage routinely available medical imaging data. The 5-year project, set...
This $306,999 Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) is focused on developing an integrated machine learning framework to accurately identify lung cancer subtypes. The key products and services to be delivered include: Establishing a gene signature-transfer machine learning model that leverages large-scale bulk and single-cell transcriptomics data, both within and beyond NIH Common Fund...
The National Cancer Institute (NCI) awarded a $1,408,844 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the Sloan-Kettering Institute for Cancer Research in New York, NY. The grant, effective July 2, 2024 through June 30, 2028, supports research to characterize the theranostic potential of Delta-Like Ligand 3 (DLL3)-targeting agents for the diagnosis and treatment of high-grade neuroendocrine carcinomas of the lung (small cell lung cancer) and prostate (neuroendocrine prostate...
This $427,095 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports the development of a novel microfluidic droplet-based platform (MDP) technology to generate and analyze a 3D biomimetic multicellular immunogenic tumor model. The goal is to establish multiple levels of hypoxia within the tumor-chip, investigate spatiotemporal interaction between the tumor microenvironment and cancer-immune cells during...
The National Cancer Institute (NCI) awarded a $400,000 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Electronic Biosciences, Inc., a small biotechnology company in San Diego, California. The goal of this 1-year project is to develop a novel nanopore-based sequencing approach that can accurately characterize repetitive DNA sequences, which are critical for understanding cancer progression but challenging to analyze using current sequencing...
This $3,787,956 federal Project Grant award, issued by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), is funding a multi-year research program at New York University School of Medicine to investigate and target replication stress in small cell lung cancer (SCLC). The program aims to understand how the SLFN11 gene and replication stress response pathways regulate chemosensitivity in SCLC subtypes, and to develop strategies to combat acquired...